Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Dermatology | Family Medicine | Internal Medicine | Pathology | Journal

Back to Journal Articles

Central Centrifugal Cicatricial Alopecia Pathogenesis Studied

Last Updated: September 21, 2012.

 

CCCA severity linked to peak itch ratings after cowhage application; indicates role for PAR-2

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Protease-activated receptor 2, which is activated by cowhage, may play a role in central centrifugal cicatricial alopecia, the most common cause of scarring hair loss in African-American women, according to research published online Sept. 17 in the British Journal of Dermatology.

FRIDAY, Sept. 21 (HealthDay News) -- Protease-activated receptor 2 (PAR-2), which is activated by cowhage, may play a role in central centrifugal cicatricial alopecia (CCCA), the most common cause of scarring hair loss in African-American women, according to research published online Sept. 17 in the British Journal of Dermatology.

To investigate the neural component of CCCA, Ghada A. Bin Saif, M.D., of the King Saud University in Riyadh, Saudi Arabia, and colleagues conducted a study involving 15 healthy African-American women and 16 African-American women with CCCA. All women underwent computerized thermosensory testing to assess warmth and heat pain thresholds. The intensity of itching was assessed following histamine iontophoresis and the application of cowhage spicules, which activates PAR-2.

The researchers found that CCCA severity correlated significantly with peak itch ratings following cowhage, but not histamine, application to the lesional scalp of women with CCCA. In both healthy women and those with CCCA, warmth and pain thresholds were higher on the crown than the occiput.

"Our results suggest a putative role for PAR-2, which is activated by cowhage, in the pathogenesis of CCCA," the authors write. "Future studies should examine PAR-2 directed therapeutics for CCCA patients. Examining for itch and other dysesthesias in CCCA patients is of vital importance to dermatologists in assessing disease severity."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Leaving Balloon in Is Safe in Urinary Sphincter Revision Next: Fewer Older People on the Street May Lead Youth to Riskier Lives

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.